导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.68% | 2984/4773 |
| 近一周 | -2.05% | 1126/5462 |
| 近一月 | -3.87% | 2035/5421 |
| 近一季 | -7.13% | 2301/5209 |
| 近半年 | 0.12% | 1198/4920 |
| 近一年 | -0.58% | 2744/4366 |
| 近两年 | 36.91% | 2014/2954 |
| 近三年 | 26.37% | 1215/2253 |
| 成立以来 | 65.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.28% 3587/4961 |
8.93% 2517/5312 |
- - |
- - |
| 2025 | 17.09% 2400/4813 |
-0.69% 2357/3635 |
2.55% 1493/4076 |
12.58% 3060/4524 |
2.12% 1079/4813 |
| 2024 | 19.69% 509/3463 |
4.96% 411/2808 |
0.42% 613/3014 |
17.02% 1287/3129 |
-2.97% 2220/3463 |
| 2023 | -7.36% 912/2656 |
1.72% 1528/2280 |
-3.68% 863/2385 |
1.43% 310/2515 |
-6.78% 1917/2655 |
| 2022 | -14.39% 368/2207 |
-12.04% 566/1919 |
9.25% 290/2016 |
-11.83% 593/2113 |
1.04% 1402/2208 |
| 2021 | -8.54% 1052/1822 |
-2.14% 587/1255 |
2.04% 1019/1330 |
-9.80% 1195/1466 |
1.55% 882/1822 |
| 2020 | 33.49% 458/1250 |
-10.26% 767/1028 |
13.10% 647/1067 |
12.79% 363/1164 |
16.62% 157/1184 |
| 2019 | 41.26% 236/1092 |
24.16% 527/754 |
4.62% 22/804 |
1.52% 392/850 |
7.13% 482/918 |
| 2018 | -19.37% 161/834 |
- - |
- - |
- - |
-12.09% 398/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实富时中国A50ETF联接A VS. 长安沪深300非周期A(740101) |